homeWelcome, sign in or click here to subscribe.login
     


 

 

Business


print  email to a friend  reprints add to mydjc  

November 8, 2019

Seattle Genetics

Bothell-based Seattle Genetics inked a licensing deal worth up to $160 million with BeiGene for an advanced preclinical cancer drug. The agent uses a proprietary Seattle Genetics antibody-based technology and is expected to advance into clinical trials in the first half of 2020. Seattle Genetics will develop it in the Americas, Europe and Japan while BeiGene will have Asia and the rest of the world. Beijing-based BeiGene focuses on cancer therapeutics.




Email or user name:
Password:
 
Forgot password? Click here.